The stock of Alder Biopharmaceuticals Inc (NASDAQ:ALDR) is a huge mover today! About 369,468 shares traded hands. Alder Biopharmaceuticals Inc (NASDAQ:ALDR) has declined 9.35% since April 4, 2016 and is downtrending. It has underperformed by 10.44% the S&P500.
The move comes after 6 months positive chart setup for the $1.22B company. It was reported on Nov, 4 by Barchart.com. We have $40.01 PT which if reached, will make NASDAQ:ALDR worth $805.20M more.
Alder Biopharmaceuticals Inc (NASDAQ:ALDR) Ratings Coverage
Out of 8 analysts covering Alder Biopharmaceuticals (NASDAQ:ALDR), 8 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Alder Biopharmaceuticals has been the topic of 10 analyst reports since August 6, 2015 according to StockzIntelligence Inc. Jefferies initiated Alder Biopharmaceuticals Inc (NASDAQ:ALDR) on Wednesday, September 9 with “Buy” rating. The stock of Alder Biopharmaceuticals Inc (NASDAQ:ALDR) has “Buy” rating given on Wednesday, April 20 by Brean Capital. On Thursday, April 21 the stock rating was reinitiated by Wells Fargo with “Outperform”. The stock of Alder Biopharmaceuticals Inc (NASDAQ:ALDR) earned “Buy” rating by Jefferies on Wednesday, July 27. The rating was initiated by Piper Jaffray with “Overweight” on Monday, October 31. Credit Suisse maintained the shares of ALDR in a report on Tuesday, March 29 with “Outperform” rating. The rating was initiated by JP Morgan with “Overweight” on Tuesday, September 13.
According to Zacks Investment Research, “Alder Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and seeks to commercialize therapeutic antibodies. It is developing monoclonal antibodies comprising ALD403, for the prevention of migraine; and Clazakizumab, in the treatment of rheumatoid arthritis and psoriatic arthritis. Alder Biopharmaceuticals Inc. is headquartered in Bothell, Washington.”
More news for Alder Biopharmaceuticals Inc (NASDAQ:ALDR) were recently published by: Fool.com, which released: “Why Alder Biopharmaceuticals Is Sky-Rocketing Today” on March 28, 2016. Nasdaq.com‘s article titled: “Oversold Conditions For Alder Biopharmaceuticals” and published on October 31, 2016 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.